Levine D S
Department of Medicine, University of Washington, Seattle, USA.
Gastroenterol Clin North Am. 1997 Sep;26(3):613-34. doi: 10.1016/s0889-8553(05)70318-6.
The management of patients with high-grade dysplasia in Barrett's esophagus is complex and controversial with regard to electing continued endoscopic biopsy surveillance until an early adenocarcinoma is detected or proceeding with partial esophagogastrectomy. Clinical recommendations to patients for either option should be individualized and based on several parameters reflecting patient and clinician factors. Available data on interpretational variation in the diagnosis of dysplasia; limitation of diagnostic errors with the use of a rigorous, systematic endoscopic biopsy protocol; new information on the apparent benign natural history of high-grade dysplasia in some patients; and the morbidity and mortality of esophageal resection all suggest that recommendation for continued endoscopic biopsy surveillance is an appropriate clinical practice in selected patients. Ongoing research investigations on high-grade dysplasia in Barrett's esophagus aim to reduce the potential for diagnostic errors, simplify cancer surveillance, and develop therapeutic interventions that are safer than but as effective as surgery.
对于巴雷特食管高级别异型增生患者的管理,在选择持续进行内镜活检监测直至检测到早期腺癌,还是进行部分食管胃切除术方面,情况复杂且存在争议。针对这两种选择向患者提供的临床建议应因人而异,并基于反映患者和临床医生因素的多个参数。关于异型增生诊断中解释差异的现有数据;使用严格、系统的内镜活检方案限制诊断错误;一些患者中高级别异型增生明显良性自然史的新信息;以及食管切除术的发病率和死亡率,所有这些都表明,对于部分患者而言,推荐持续进行内镜活检监测是一种合适的临床做法。目前关于巴雷特食管高级别异型增生的研究旨在减少诊断错误的可能性、简化癌症监测,并开发比手术更安全但效果相同的治疗干预措施。